Background: Malignancy-associated hypercalcemia (MAHC) is the most common cause of hypercalcemia among hospitalized patients. MAHC can result from the production of parathyroid hormone related peptide (PTHrP) which is known as humoral hypercalcemia of malignancy (HHM). HHM is commonly thought to account for approximately 80% of MAHC.
Methods: We conducted a 12-year review of PTHrP testing at our institution to establish the prevalence of HHM among patients with MAHC.
Results: A total of 524 PTHrP immunoassays were performed during the study period of which 470 tests qualified for inclusion in the analysis. Evidence of malignancy was found for 242 of 470 patients (51%). No etiology could be determined for 98 cases of MAHC (40%) and increased PTHrP contributed to 92 cases (38%) of MAHC. Age, race and gender were not associated with HHM. Increased PTHrP was observed at initial malignancy diagnosis in 20% of cases. PTHrP was never increased outside of the context of malignancy.
Discussion: The prevalence of HHM among patients with MAHC is likely to be lower than previously described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2015.12.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breast Adenocarcinoma and Cold Agglutinin Disease: A Paraneoplastic Syndrome.
Cureus
November 2024
Department of Oncology, Medical University of South Carolina, Charleston, USA.
Autoimmune hemolytic anemia is a disorder that is characterized by the destruction of red blood cells through an autoimmune process, such as temperature-dependent antibodies. The two predominant types, cold agglutinin and warm agglutinin disease, typically possess different underlying etiologies. Prompt recognition and workup of autoimmune hemolytic anemia should be prioritized to potentially uncover any underlying primary cause, such as malignancy.
View Article and Find Full Text PDFClinical and Biochemical Profiles of Hospitalized Patients with Hypercalcaemia from a Tertiary Care Centre in North India.
touchREV Endocrinol
October 2024
Department of Endocrinology, Bharti Hospital & BRIDE, Karnal, India.
The profile of hypercalcaemia in hospitalized patients in India seems to be changing. However, studies evaluating the profile of hypercalcaemia in hospitalized settings in India are extremely limited. This prospective study aims to evaluate the clinical and biochemical profile of hospitalized patients with hypercalcaemia from a tertiary care centre in north India.
View Article and Find Full Text PDFThe Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review).
Biology (Basel)
August 2024
Department of Internal Medicine and Gastroenterology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Article Synopsis
- - Cholangiocarcinomas (CCAs) are complex malignant tumors from the biliary epithelium, with increasing global incidence and various risk factors such as chronic liver diseases, lifestyle choices, and genetic factors
- - The review highlights the endocrine features related to CCAs, including associations with conditions like obesity and diabetes, alongside various paraneoplastic syndromes that manifest in patients
- - Humoral hypercalcemia is noted as the most common paraneoplastic syndrome in CCAs, signaling poor prognosis and requiring treatment beyond the typical cancer therapy
Parathyroid Hormone Related Protein Mediated Hypercalcaemia Due to Metastatic Squamous Cell Carcinoma Originating from Pilonidal Disease: A Case Report.
Br J Hosp Med (Lond)
August 2024
Department of Histopathology, Mater Dei Hospital, Birkirkara, Malta.
A 56-year-old male presented with a longstanding, gradually enlarging, painful, skin lesion over the natal cleft. This was initially thought to be a pilonidal abscess but, following multiple surgeries, he was diagnosed with Stage IVb squamous cell carcinoma of the natal cleft skin with bilateral inguinal lymph node metastases and subcutaneous metastatic deposits. Complete surgical cure was not possible.
View Article and Find Full Text PDFA Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy.
Cureus
April 2024
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Minnesota School of Medicine, Minneapolis, USA.
Article Synopsis
- Humoral hypercalcemia of malignancy (HHM), primarily caused by elevated parathyroid hormone-related peptide (PTHrP), is uncommon in cholangiocarcinoma but can lead to serious complications.
- A case study highlighted a 63-year-old male with locally advanced FGFR fusion-positive intrahepatic cholangiocarcinoma who experienced recurrent episodes of HHM, with the first occurring 15 months post-diagnosis and subsequent episodes indicating disease progression.
- The case emphasizes the need for early detection and treatment of HHM in cholangiocarcinoma, as well as the potential for integrating knowledge of molecular changes to develop targeted therapies and enhance patient risk assessment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!